Hematologic Malignancies Program News Today

Indiana University School of Medicine scientists are on a mission to understand why hematopoietic stem cells, responsible for producing all types of mature bloo

Unprecedented shortages of key cancer drugs in the United States could disrupt treatment for tens of thousands of patients with various forms of the disease in the coming months unless hospitals take action, experts say.

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

10.08.2022 - Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings ...

/PRNewswire/ -- Ten years ago, Tom and Kari Whitehead came to Childrens Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter,...

/PRNewswire/ -- Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia...

/PRNewswire/ -- Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia